<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02671903</url>
  </required_header>
  <id_info>
    <org_study_id>15HH2828</org_study_id>
    <nct_id>NCT02671903</nct_id>
  </id_info>
  <brief_title>The His Optimised Pacing Evaluated for Heart Failure Trial (HOPE-HF).</brief_title>
  <acronym>HOPE-HF</acronym>
  <official_title>AV Optimisation Delivered With Direct His Bundle Pacing, in Patients With Heart Failure, Long PR Without Left Bundle Branch Block: Randomised Multi-centre Clinical Outcome Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>British Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre, prospective randomised double-blinded cross over study, recruiting a
      sub-population of patients with heart failure.

      All patients will be implanted with a CRT (Cardiac Resynchronisation Therapy) pacemaker with
      one of the leads positioned on the His bundle in order to obtain direct His-bundle capture.
      There will be a 2-month run-in period where the device is not active.

      A double-blinded cross-over design will then be employed to investigate the effect of His
      bundle pacing. Patients will be allocated in random order to six month treatment periods in
      each of the following two states (1) No pacing; (2) AV optimised direct His-bundle pacing.
      Endpoint measurements will be taken at baseline, 6 months and 12 months post randomisation.
      Treatment allocation will be blinded to the endpoint assessor and the patient.

      126 patients will be needed to detect the expected effect size on the primary endpoint with
      90% power. A total of 160 patients will be recruited to allow for patient drop-out.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients entering the study will attend for implantation of a CRT pacemaker device with one
      lead positioned on the His bundle. This will be performed either at the patient's local
      hospital or at Imperial College NHS healthcare Trust, no later than 4 months after the
      patient's screening visit.

      All patients will be implanted with a Pacemaker or Implantable cardioverter defibrillator
      (ICD). In all patients a pacing lead will be positioned in the right atrium (typically the
      right atrial appendage). All patients will have a pacemaker lead positioned on the His bundle
      in order to obtain direct His-bundle capture. If it is not possible to successfully implant a
      His-bundle lead with selective direct His bundle capture or non-selective capture with &lt; 40ms
      prolongation of the QRS duration, then a lead will be implanted in a lateral branch of the
      coronary sinus.

      In patients who do not have an indication for an Implantable cardioverter defibrillator (ICD)
      a second ventricular lead will be implanted in a lateral branch of the coronary sinus. If
      direct His pacing has not been successfully achieved then a further lead will be positioned
      at the RV apex. In patients who do have an indication for an Implantable cardioverter
      defibrillator the ICD lead will be positioned in the right ventricle (either RV apex or RV
      septum).

      AV delay optimisation will be performed using acute non-invasive blood pressure acquired
      using the Finometer device (Finapres Medical systems, Netherlands). The BHF (British Heart
      Foundation) alternation protocol will be used in order to minimise the effect of background
      noise.

      After implantation of the device there will be a 2 month run-in period prior to
      randomisation, the device will be programmed not to deliver His bundle pacing therapy during
      this period.(Back up only pacing and defibrillator function will be enabled).

      Two months after patients are implanted with their device, patients will be randomised to
      either receive active pacing treatment or back up only pacing (pacemaker programmed to VVI 30
      bpm). After a further 6 months they will be crossed over to the alternative treatment arm.
      Treatment allocation will be obtained using an Interactive Web Response System (IWRS)
      programmed with a randomisation schedule provided by the trial statistician. Appropriate
      blocking will be used.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in exercise capacity.</measure>
    <time_frame>Baseline, 6 months and 12 months post randomisation.</time_frame>
    <description>Measured using peak oxygen uptake (VO2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Echocardiographic measurement of left ventricular function (Ejection Fraction)</measure>
    <time_frame>Baseline, 6 months and 12 months post randomisation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in B-type Naturietic Peptide (BNP).</measure>
    <time_frame>Baseline, 6 months and 12 months post randomisation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of Life Scores.</measure>
    <time_frame>Baseline, 6 months and 12 months post randomisation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness analysis (using a custom designed Resource Utilisation Questionnaire)</measure>
    <time_frame>Baseline.</time_frame>
    <description>The analysis will be based on an intention-to-treat (ITT) principle. The economic evaluation will compare incremental costs and incremental outcomes of the direct His-bundle pacing against the standard medical care. The study will be performed from a societal perspective, which takes all relevant cost-categories and effects into account. The economic evaluation will consist of two parts, a cost-effectiveness analysis (CEA) and a cost utility analysis (CUA). In the CEA the incremental cost-effectiveness ratio (ICER) will be expressed as the incremental costs per point improvement in exercise capacity in peak VO2. The primary outcome measure in the CUA will be Qualitative Adjusted Life Years (QALYs), based on the EQ5D and Minnesota questionnaire scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in percentage pacing.</measure>
    <time_frame>Baseline, 6 months and 12 months post randomisation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in arrythmia burden (%).</measure>
    <time_frame>Baseline, 6 months and 12 months post randomisation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pacing thresholds (Volts).</measure>
    <time_frame>Baseline, 6 months and 12 months post randomisation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in R wave amplitude.</measure>
    <time_frame>Baseline, 6 months and 12 months post randomisation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lead impedance (Ohms).</measure>
    <time_frame>Baseline, 6 months and 12 months post randomisation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy time during device insertion.</measure>
    <time_frame>Baseline.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Pacemaker: AV optimised, His pacing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will remain in this arm for 6 months before being crossed-over. See below intervention details.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No pacing</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will remain in this arm for 6 months before being crossed-over. The pacemaker will be programmed to VVI 30 bpm. Dynamic AV delay will be programmed off throughout the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pacemaker: AV optimised, His pacing.</intervention_name>
    <description>Direct His bundle pacing: a Medtronic Select Secure 3830 pacing lead will be positioned at the His bundle. If selective direct His bundle pacing cannot be achieved then non-selective His bundle pacing will be accepted. AV delay optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems, Netherlands).</description>
    <arm_group_label>Pacemaker: AV optimised, His pacing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 or above

          -  Ventricular Ejection Fraction (EF) &lt; 40%; BNP needs to be ≥250ng/L for patients with
             EF 36-40%

          -  New York Heart Association (NYHA) class II-IV

          -  PR interval ≥200ms

          -  Narrow QRS duration (≤140ms) or prolonged QRS duration with typical Right Bundle
             Branch Block (RBBB) morphology on 12 lead ECG and sinus rhythm

        Exclusion Criteria:

          -  Permanent or persistent atrial fibrillation (AF)

          -  Paroxysmal atrial fibrillation with history of sustained AF (more than 24 hours) in
             the 6 months prior to screening

          -  Patients who are unable to perform cardiopulmonary exercise testing

          -  Other serious medical condition with life expectancy of less than 1 year

          -  Lack of capacity to consent

          -  Pregnancy

          -  Contraindication to use of the relevant study device or leads (as per current manuals
             from manufacturer)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zachary Whinnett, BMBS MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Senior Lecturer in Cardiac Electrophysiology, Consultant Cardiologist and Electrophysiologist</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zachary Whinnett, BMBS MRCP</last_name>
    <phone>+44(0)208 383 4967</phone>
    <email>Zachary.Whinnett@imperial.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Keene, MbCHb MRCP</last_name>
    <phone>+44(0)208 383 7380</phone>
    <email>drkeene@doctors.org.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West Hertfordshire Hospitals NHS Trust</name>
      <address>
        <city>Watford</city>
        <state>Hertfordshire</state>
        <zip>WD18 0HB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phil Moore</last_name>
    </contact>
    <investigator>
      <last_name>Dr Philip Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Basildon and Thurrock Hospitals NHS Foundation Trust</name>
      <address>
        <city>Basildon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Farwell</last_name>
    </contact>
    <investigator>
      <last_name>David Farwell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Leyva</last_name>
    </contact>
    <investigator>
      <last_name>Francisco Leyva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol NHS Foundation Trust</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Duncan</last_name>
    </contact>
    <investigator>
      <last_name>Edward Duncan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western Sussex Hospitals NHS Foundation Trust</name>
      <address>
        <city>Chichester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Tanner</last_name>
    </contact>
    <investigator>
      <last_name>Mark Tanner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medway NHS Foundation Trust</name>
      <address>
        <city>Kent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaumik Adhya</last_name>
    </contact>
    <investigator>
      <last_name>Shaumik Adhya</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Trust</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre Ng</last_name>
    </contact>
    <investigator>
      <last_name>Andre Ng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Zachary Whinnett, BMBS MRCP</last_name>
      <phone>+44(0)208 383 4967</phone>
      <email>z.whinnett@imperial.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Dr Daniel Keene, MbCHb MRCP</last_name>
      <phone>+44(0)208 383 7380</phone>
      <email>drkeene@doctors.org.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Dr Zachary Whinnett</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Daniel Keene</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phil Moore</last_name>
    </contact>
    <investigator>
      <last_name>Phil Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aldo Rinaldi</last_name>
    </contact>
    <investigator>
      <last_name>Aldo Rinaldi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Scott</last_name>
    </contact>
    <investigator>
      <last_name>Paul Scott</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brompton &amp; Harefield NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mason</last_name>
    </contact>
    <investigator>
      <last_name>Mark Mason</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital NHS Foundation Trust</name>
      <address>
        <city>Papworth Everard</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharad Agarwal</last_name>
    </contact>
    <investigator>
      <last_name>Sharad Agarwal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Kyricou</last_name>
    </contact>
    <investigator>
      <last_name>Andreas Kyricou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Western Hospitals NHS Foundation Trust</name>
      <address>
        <city>Swindon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Badri Chandrasekaran</last_name>
    </contact>
    <investigator>
      <last_name>Badri Chandrasekaran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>January 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2016</study_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

